share_log

Barclays Maintains Equal-Weight on Chemours, Lowers Price Target to $30

Barclays Maintains Equal-Weight on Chemours, Lowers Price Target to $30

巴克莱维持Chemours的同等权重,将目标股价下调至30美元
Benzinga Real-time News ·  2022/09/27 06:41

Barclays analyst Michael Leithead maintains Chemours (NYSE:CC) with a Equal-Weight and lowers the price target from $46 to $30.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发